1 Elacestrant Versus Fulvestrant or Aromatase Inhibitor in a Phase 3 Trial Evaluating Elacestrant, an Oral Selective Estrogen Receptor Degrader Versus Standard-of- Care Endocrine Monotherapy for ER+/HER2– Advanced/Metastatic Breast Cancer
7 EMERALD Phase 3 Trial of Elacestrant Versus Standard-of- Care Endocrine Therapy in Patients With ER+/HER2– Metastatic Breast Cancer: Updated Results by Duration of Prior CDK4/6i in Metastatic Setting
26 Subgroup Analysis of Patients With No Prior Chemotherapy in EMERALD: A Phase 3 Trial Evaluating Elacestrant, an Oral Selective Estrogen Receptor Degrader (SERD), Vs Investigator’s Choice of Endocrine Monotherapy for ER+/HER2– Advanced/ Metastatic Breast Cancer (mBC)
Future Perspectives in HER2+ mBC
The panel closes their discussion by musing on the future of HER2 mBC treatments.
Leptomeningeal Metastases in HER2+ mBC
A discussion on the prevalence and treatment difficulties of leptomeningeal metastases in HER2+ mBC.
Systemic Therapy Before Whole Brain Radiation for HER2+ mBC with Brain Metastases
The panel discusses the systemic therapy options for patients with HER2+ mBC with brain metastases before moving to whole brain radiation therapy.
Case Presentation: A 62-Year-Old Woman with HER2+ mBC with Pulmonary and Brain Metastases
Andrew Brenner, MD, presents the case of a 62-year-old patient with stage II HER2+ mBC presenting with both pulmonary and brain metastases.
Managing Adverse Events of Tucatinib in Patients with HER2+ mBC with Brain Metastases
Joyce O’Shaughnessy, MD, starts a conversation on managing the adverse events of tucatinib therapy in patients with HER2+ mBC with brain metastases.
Treatment Approaches in HER2+ mBC with Brain Metastases
The panel reviews the treatment approaches for HER2+ mBC with active brain metastases and the factors to consider during treatment decision-making.
Case Presentation: A 60-Year-Old Woman with HER2+ mBC with Brain Metastases
Virginia Kaklamani, MD, presents the case of a 60-year-old patient with stage III HER2+ mBC with brain metastases.
Third-Line Treatment Options for HER2+ mBC after Progression on Trastuzumab Deruxtecan
Heather McArthur, MD, describes what treatment options she would consider in the third-line setting for HER2+ mBC.
Screening for Brain Metastases in HER2+ Breast Cancer
Andrew Brenner, MD, explains when physicians should screen patients with HER2+ breast cancer for brain metastases.
Trastuzumab Deruxtecan Maintenance after First-Line Therapy for HER2+ mBC
Joyce O’Shaughnessy, MD, starts a discussion on maintenance therapy with trastuzumab deruxtecan in patient with HER2+ mBC.
Case Presentation: A 69-Year-Old Woman with HER2+ Metastatic Breast Cancer (mBC)
Heather McArthur, MD, presents the case of a 69-year-old woman with stage II HER2+ mBC for discussion.
HER2+ Breast Cancer Clinical Pearls
Advice for community physicians treating HER2+ breast cancer.
HER2+ Breast Cancer and the Role of Maintenance Therapies
Dr. Virginia Kaklamani discusses the role of maintenance therapies for HER2+ breast cancer.
Clinical Trial Data in HER2+ Breast Cancer
Virginia Kaklamani, MD, DSc, provides an overview of the goals of care for HER2+ breast cancer.
HER2+ Breast Cancer: Frontline Treatment Options
A review of the currently available frontline treatment options for HER2+ breast cancer.
Goals of Care for HER2+ Breast Cancer
2 Clarke Drive Cranbury, NJ 08512